PL3097926T3 - Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria - Google Patents

Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria

Info

Publication number
PL3097926T3
PL3097926T3 PL16175274T PL16175274T PL3097926T3 PL 3097926 T3 PL3097926 T3 PL 3097926T3 PL 16175274 T PL16175274 T PL 16175274T PL 16175274 T PL16175274 T PL 16175274T PL 3097926 T3 PL3097926 T3 PL 3097926T3
Authority
PL
Poland
Prior art keywords
eimeria
compositions
methods
immune responses
enhancing immune
Prior art date
Application number
PL16175274T
Other languages
English (en)
Inventor
Walter Bottje
Billy Hargis
Luc Berghman
Young Min Kwon
Kimberly Cole
Mandy Cox
Sherryll Layton
Saeed El-Ashram
John Barta
Guillermo Tellez
Original Assignee
The Board Of Trustees Of The University Of Arkansas
The Texas A&M University System
University Of Guelph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The University Of Arkansas, The Texas A&M University System, University Of Guelph filed Critical The Board Of Trustees Of The University Of Arkansas
Publication of PL3097926T3 publication Critical patent/PL3097926T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/455—Eimeria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PL16175274T 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria PL3097926T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98461207P 2007-11-01 2007-11-01
PCT/US2008/082254 WO2009059298A2 (en) 2007-11-01 2008-11-03 Compositions and methods of enhancinc immune responses to eimeria
EP08843740.5A EP2214701B1 (en) 2007-11-01 2008-11-03 Compositions and methods of enhancing immune responses to eimeria
EP16175274.6A EP3097926B1 (en) 2007-11-01 2008-11-03 Compositions and methods of enhancing immune responses to eimeria

Publications (1)

Publication Number Publication Date
PL3097926T3 true PL3097926T3 (pl) 2020-04-30

Family

ID=40591796

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16175274T PL3097926T3 (pl) 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
PL08843740T PL2214701T3 (pl) 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08843740T PL2214701T3 (pl) 2007-11-01 2008-11-03 Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria

Country Status (14)

Country Link
US (3) US8956849B2 (pl)
EP (2) EP3097926B1 (pl)
JP (1) JP5480812B2 (pl)
CN (2) CN103893747B (pl)
AU (1) AU2008318357B2 (pl)
BR (1) BRPI0819229B1 (pl)
CA (3) CA2704422C (pl)
DK (2) DK2214701T3 (pl)
ES (2) ES2761693T3 (pl)
HU (2) HUE047164T2 (pl)
NZ (2) NZ585777A (pl)
PL (2) PL3097926T3 (pl)
PT (2) PT2214701T (pl)
WO (1) WO2009059298A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857038B1 (en) * 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US9125854B2 (en) 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) * 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
NO2525817T3 (pl) 2010-01-21 2018-01-06
BR112012031211A2 (pt) * 2010-06-09 2018-01-30 Univ Arkansas métodos e vacina para reduzir a infecção causada pelo campylobacter
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
US9580482B2 (en) 2012-02-17 2017-02-28 Children's Medical Center Corporation Conformation-stabilized TRAP antigens
EP2956165B1 (en) * 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
JP7175612B2 (ja) 2015-05-08 2022-11-21 ノボザイムス アクティーゼルスカブ アルファ－アミラーゼ多様体およびこの多様体をコードするポリヌクレオチド
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2021012471A (es) 2019-04-11 2022-01-04 Univ Arkansas Aptameros de adn especificos de cd40 como adyuvantes de vacunas.
CN110468069B (zh) * 2019-08-19 2020-11-06 中国水产科学研究院长江水产研究所 一种干酪乳杆菌yfi-5及其在抗鲤疱疹病毒ii型中的应用
CN113304254A (zh) * 2021-06-07 2021-08-27 吉林大学 一种微小隐孢子虫Cp15重组侵入型乳酸菌活载体疫苗

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE180280T1 (de) * 1991-03-05 1999-06-15 Wellcome Found Expression rekombinanter proteine in attenuierten bakterien
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
KR100283541B1 (ko) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
US7405270B2 (en) * 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
CA2143299A1 (en) * 1992-09-04 1994-03-17 University Of Saskatchewan Novel bacterial vaccines using vaccine strains of pathogenic bacteria
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
US5565321A (en) * 1993-01-22 1996-10-15 Immunex Corporation Detection of mutations in a CD40 ligand gene
WO1995014487A1 (en) 1993-11-24 1995-06-01 The Australian National University Treatment of viral disease with cd40l peptide
DK0763057T3 (da) * 1994-04-28 2006-03-27 Boehringer Ingelheim Pharma Fremgangsmåde til proliferering og differentiering af B celler og anvendelse deraf
AU699291B2 (en) 1995-03-01 1998-11-26 Immunex Corporation Method for stimulating an immune response
MX9709447A (es) 1995-06-07 1998-02-28 Immunex Corp Nueva muteina cd4ol.
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) * 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6306387B1 (en) * 1997-05-29 2001-10-23 The Research Foundation Of State University Of New York Antigen delivery system
US20030045492A1 (en) 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6969609B1 (en) * 1998-12-09 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Serivces Recombinant vector expressing multiple costimulatory molecules and uses thereof
CA2223225A1 (en) 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
JP2001526241A (ja) 1997-12-19 2001-12-18 イミュネックス・コーポレーション Ｈｉｖ感染に対する感受性を低下させるための方法
GB9806449D0 (en) * 1998-03-25 1998-05-27 Peptide Therapeutics Ltd Attenuated bacteria useful in vaccines
US6190669B1 (en) * 1998-05-13 2001-02-20 University Of Maryland, Baltimore Attenuated mutants of salmonella which constitutively express the Vi antigen
WO2000014240A2 (en) * 1998-09-04 2000-03-16 Creatogen Aktiengesellschaft Attenuated salmonella sp12 mutants as antigen carriers
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
JP2003508016A (ja) 1999-04-16 2003-03-04 エフ．ホフマン−ラ ロシュ アーゲー Ｃｄ４０／ｃｄ４０ｌキメラポリペプチドをコードする核酸、それらの生成方法及びそれらの使用
EP1067194A1 (en) 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
EP1246643A4 (en) * 1999-10-14 2005-05-11 Jeffery A Ledbetter DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
MXPA00012796A (es) * 1999-12-28 2002-05-23 Akzo Nobel Nv Vacuna de salmonella.
DE60136334D1 (en) 2000-02-02 2008-12-11 Us Health Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
AU5695701A (en) * 2000-03-17 2001-10-03 Upjohn Co Salmonella vaccine materials and methods
GB0015426D0 (en) * 2000-06-24 2000-08-16 Univ Southampton Method for generating soluble highly multimeric proteins
AU2001273009A1 (en) 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
AU2002221780A1 (en) 2000-10-31 2002-05-15 F.Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1407004B1 (en) * 2001-05-15 2009-08-05 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Ex-vivo priming for generating cd40-ligand specific cytotoxic t lymphocytes to treat autoimmune and allergic disease
AU2002316560B2 (en) * 2001-07-06 2008-05-01 Abic Biological Laboratories Ltd Nucleic acids encoding a recombinant 250 kDa antigen from Sporozoites/Merozoites of Eimeria maxima and their uses
ZA200400479B (en) * 2001-07-06 2006-05-31 Abic Biolog Lab Teva Nucleic acids encoding recombinant 56 a 82 KDA antigens from gametocytes of Eimeria maxima and their use
ITMI20011986A1 (it) 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US7378089B2 (en) 2001-10-02 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
PL208287B1 (pl) * 2001-12-21 2011-04-29 Immunex Corp Polipeptyd fuzyjny, sposób jego wytwarzania oraz kodujący go kwas nukleinowy, komórka gospodarza, rekombinowany wektor oraz sposób jego konstruowania
KR100965026B1 (ko) * 2002-02-13 2010-06-21 이뮤놀로지 래보러토리스 인코포레이티드 미생물 감염증을 치료하기 위한 조성물 및 방법
US6923958B2 (en) * 2002-03-02 2005-08-02 The Scripps Research Institute DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
WO2003096812A1 (en) * 2002-04-15 2003-11-27 Washington University Regulated attenuation of live vaccines to enhance cross protective immunogenicity
US7495090B2 (en) * 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US20050181994A1 (en) * 2003-01-06 2005-08-18 Xencor, Inc. Novel variants of CD40L protein
US7754209B2 (en) * 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
WO2005035570A2 (en) 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein
WO2005058950A2 (en) 2003-12-11 2005-06-30 Sidney Kimmel Cancer Center Methods for generating immunity to antigen
US8828957B2 (en) * 2003-12-11 2014-09-09 Microvax, Llc Methods for generating immunity to antigen
WO2005113598A2 (en) 2004-05-21 2005-12-01 Xencor, Inc. Tnf super family members with altered immunogenicity
US8513008B2 (en) * 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
US20080145931A1 (en) 2004-10-07 2008-06-19 Argos Therapeutics, Inc. Mature Dendritic Cell Compositions and Methods of Culturing Same
WO2006105972A1 (en) 2005-04-07 2006-10-12 Universite Libre De Bruxelles Transgenic organism expressing cd40l and uses thereof
WO2006130525A2 (en) * 2005-05-31 2006-12-07 Sidney Kimmel Cancer Center Methods for immunotherapy of cancer
JP2009511452A (ja) 2005-10-07 2009-03-19 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ Ｃ型肝炎の予防および治療のための免疫刺激物質の組合せ
AU2006311752A1 (en) * 2005-11-07 2007-05-18 Sidney Kimmel Cancer Center CD40 ligand fusion protein vaccine
DE102005054643B3 (de) 2005-11-10 2007-02-15 Assa Abloy Sicherheitstechnik Gmbh Schließzylinder
WO2007054658A1 (en) 2005-11-14 2007-05-18 King's College London Control of immune responses
CU23576A1 (es) * 2006-02-28 2010-09-30 Ct Ingenieria Genetica Biotech Antígenos vacunales quiméricos contra el virus de la influenza aviar
WO2007103048A2 (en) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
US8802419B2 (en) * 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
FR2898905B1 (fr) * 2006-03-24 2008-05-09 Rhodia Recherches & Tech Composition polyisocyanate a proprietes anti-chocs ameliorees
US20090246220A1 (en) * 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
WO2008109825A2 (en) 2007-03-08 2008-09-12 Mayo Foundation For Medical Education And Research Inducing immune-mediated tumor cell death
CN101024076B (zh) * 2007-03-29 2010-08-18 中国农业大学 球虫的新用途
ES2657801T3 (es) * 2007-07-10 2018-03-06 Apogenix Ag Proteínas de fusión de colectina de la superfamilia de TNF
US9125854B2 (en) * 2007-10-30 2015-09-08 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
PT2214701T (pt) 2007-11-01 2016-11-02 Univ Guelph Composições e métodos de potenciar respostas imunes a eimeria
EP3103875A1 (en) * 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
US8316310B2 (en) 2008-08-05 2012-11-20 International Business Machines Corporation System and method for human identification proof for use in virtual environments
EP2184229B1 (en) * 2008-11-11 2012-10-17 AGUSTAWESTLAND S.p.A. Helicopter rotor
US20100150958A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. Methods and Compositions for Use of a Coccidiosis Vaccine
NO2525817T3 (pl) * 2010-01-21 2018-01-06
KR20220116585A (ko) * 2011-10-11 2022-08-23 비엘라 바이오, 인크. Cd40l 특이적 tn3 유래 스카폴드 및 이의 사용 방법
US20140079704A1 (en) * 2012-09-11 2014-03-20 The Texas A&M University System BI-Specific Diabodies For Masking And Targeting Vaccines
AU2013338153B2 (en) * 2012-10-29 2018-06-21 The Board Of Trustees Of The University Of Arkansas Novel mucosal adjuvants and delivery systems
EP2956165B1 (en) * 2013-02-14 2019-09-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
CN105142653B (zh) * 2013-03-15 2019-11-15 阿肯色大学评议会 增强对肠病原体免疫应答的组合物和方法
CN106535932A (zh) * 2014-06-05 2017-03-22 阿肯色大学评议会 抗体引导的疫苗和用于产生快速成熟的免疫应答的方法
WO2016054225A1 (en) * 2014-09-30 2016-04-07 Stc.Unm Plasmid delivery in the treatment of cancer and other disease states
WO2017172981A2 (en) * 2016-03-29 2017-10-05 University Of Southern California Chimeric antigen receptors targeting cancer
UA123111C2 (uk) * 2016-05-27 2021-02-17 Еббві Байотерапьютікс Інк. Антитіло до cd40 та його застосування
IL308824A (en) * 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof

Also Published As

Publication number Publication date
CA3051748A1 (en) 2009-05-07
EP2214701A2 (en) 2010-08-11
WO2009059298A2 (en) 2009-05-07
DK2214701T3 (en) 2016-12-12
JP2011503003A (ja) 2011-01-27
HK1146575A1 (zh) 2011-06-24
US20180333474A1 (en) 2018-11-22
PL2214701T3 (pl) 2017-01-31
CN103893747B (zh) 2016-01-06
DK3097926T3 (da) 2019-12-16
PT2214701T (pt) 2016-11-02
CA2704422A1 (en) 2009-05-07
CA3051748C (en) 2022-07-12
CN103893747A (zh) 2014-07-02
ES2761693T3 (es) 2020-05-20
AU2008318357A1 (en) 2009-05-07
CA3156538C (en) 2023-12-12
US10842858B2 (en) 2020-11-24
CA2704422C (en) 2019-09-24
US8956849B2 (en) 2015-02-17
BRPI0819229A2 (pt) 2015-05-05
HUE047164T2 (hu) 2020-04-28
CN101969990A (zh) 2011-02-09
EP3097926A1 (en) 2016-11-30
EP2214701B1 (en) 2016-08-03
EP2214701A4 (en) 2011-06-01
EP3097926B1 (en) 2019-10-02
CA3156538A1 (en) 2009-05-07
US20110111015A1 (en) 2011-05-12
ES2599905T3 (es) 2017-02-06
PT3097926T (pt) 2020-01-08
WO2009059298A8 (en) 2010-08-05
JP5480812B2 (ja) 2014-04-23
AU2008318357B2 (en) 2015-01-22
US10016493B2 (en) 2018-07-10
CN101969990B (zh) 2014-07-09
NZ585777A (en) 2012-09-28
HUE030655T2 (en) 2017-05-29
BRPI0819229B1 (pt) 2019-01-22
US20150216954A1 (en) 2015-08-06
NZ601880A (en) 2013-12-20
WO2009059298A3 (en) 2009-09-24
AU2008318357A2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
PT3097926T (pt) Composições e métodos de potenciação das respostas imunitárias frente a eimeria
EP2066339A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING IMMUNE RESPONSES
EP2334185A4 (en) COMPOSITIONS AND METHODS FOR USE OF (R) -PRAMIPEXOL
IL208946A0 (en) Immunomodulating compositions and methods of use thereof
SI2640842T1 (sl) Postopki in sestavki za induciranje imunskega odziva na EGFRvIII
EP2231665A4 (en) NEW COMPOSITIONS AND METHODS OF USE
ZA201101641B (en) Use of mtor inhibitors to enhance t cell immune responses
IL201364A0 (en) Gas-effusing compositions and methods of making and using same
IL220715A0 (en) Nutritive compositions and methods of using same
GB0801479D0 (en) Improvements to methods of in field analysis
EP3610887B8 (en) Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
ZA201003964B (en) Compositions for and methods of enhancing the immune response to antigens
GB0812890D0 (en) Compositions and methods of making compositions
ZA201102207B (en) Cinnamandehyde-allicin compositions and their method of use
IL247929B (en) Stable compositions of 595–sns and methods for their preparation
IL207827A0 (en) Apoaequorin-containing compositions and methods of using same
ZA200908300B (en) Natural honey-containing compositions and method of preparation
PL2328402T3 (pl) Sposoby i kompozycje do wydłużenia okresu przechowywania owoców
ZA201100114B (en) Nutritive compositions and methods of using same
EP2381950A4 (en) COMPOSITIONS AND METHOD FOR THEIR USE
SI2401400T1 (sl) Metode in sestavki za ocenjevanje kroničnih avtoimunskih bolezni
AU2009900926A0 (en) Compositions and methods for enhancing immune responses